While this cancer often progresses slowly and may not require immediate treatment, it can be aggressive and spread to other ...

A new gold-based drug slows tumor growth by 82% in animals and targets cancer cells more precisely than chemotherapy.

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

Prostate cancer is the second-leading cause of cancer death among American men. With 1 in 8 facing this diagnosis over his ...

Research reveals a concerning link between packaged juices, sugary drinks, and a heightened cancer risk. These beverages ...

Both rare and aggressive, triple-negative breast cancer accounts for 10-15% of all breast cancers. Dr. Bhardwaj says, “TNBC ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Initial research suggests this saliva test can be more accurate at identifying men who are at high risk of cancer than the prostate-specific antigen blood test.

Early cancer detection often marks the difference between successful treatment and grave outcomes. Understanding warning ...

AstraZeneca PLC on Monday said its Truqap combination in a type of prostate cancer showed a statistically significant improvement in a form of progression-free survival. The Cambridge, England-based ...

Scientists at Weill Cornell Medicine have uncovered a critical mechanism driving the growth of treatment-resistant prostate ...

Chunhui Han, PhD, discusses the potential feasibility of the integration of Gallium 68 PSMA-11 in biology-guided radiotherapy ...